Bringing Transformational Medicines to Patients Through Innovation

As a global innovative biotech company, we are passionate about creating transformational therapies through innovation to address unmet medical needs in oncology for patients worldwide.

Corporate Presentation

Find out more

Innovation in 3 Generations

Monoclonal Antibody

Lemzoparlimab CD47
Uliledlimab CD73

Bi-Specific Antibody

Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB

Super Antibody

mRNA, Probody
AI Design, Alphabody

Monoclonal Antibody

Lemzoparlimab CD47
Uliledlimab CD73

Bi-Specific Antibody

Givastomig Claudin 18.2 x 4-1BB
TJ-L14B PD-L1 x 4 -1BB

Super Antibody

mRNA, Probody
AI Design, Alphabody

Latest News

Press Releases

2023.05.26

I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023

The Company reports encouraging clinical results of uliledlimab at the ASCO Annual Meeting.

2023.04.26

I-Mab Announces Poster Presentation of Proprietary CD73 Antibody Uliledlimab at ASCO 2023

The Company will present a poster featuring the latest clinical data of uliledlimab in combination with PD-1 therapy in NSCLC at ASCO 2023.

2023.04.25

I-Mab Announces Positive Outcome in Arbitration Relating to Agreements with Tracon

Award is an important victory for I-Mab and its shareholders on multiple levels, ending the multi-year long dispute.

Our Transformative Journey Driven by Global Ambition

Founded

I-Mab was established in June 2016

Series A Financing

I-Mab completed Series A financing, raising $58 million

Merger & Series B Financing

Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing

Series C Financing

I-Mab successfully raised $227 million in Series C Financing

Nasdaq Listing

I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company

AbbVie Global Partnership

I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab

Private Placement with Hillhouse Capital-Led Consortium

I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium

Global Footprint

I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou

Jumpcan Partnership

I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China

Moving Forward Together

At I-Mab, we are tackling the most challenging scientific problems

Our People

“Clinical researchers are real life superheroes providing innovative treatments to those in need.”

I-Mab Employee

“I'm inspired by my colleagues' dedication to excellence in the work that we do; their kindness and care make it easy to work together on challenging projects.”

I-Mab Employee

“At I-Mab, gender inclusivity is not a tagline. The Company provides various platforms for female employees to flourish. We feel much supported in our personal and career development.”

I-Mab Employee